Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVIGEN(avgn) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (210)	7/7/2002 12:06:31 PM
From: John McCarthy	Read Replies (1) \| Respond to of 228

Marc - Please don't respond to this - (I just wanted you to be aware of it .....) From July 5th - PBS SHOW - Wall Street Week by AG Edwards analysts Craig Hittle Alex West "Avigen represents the premier AAV (adeno-associated virus) company with the first potential cure for hemophilia patients. This name sports: a real product soon to deliver Phase 2 results (second half - 2002), a collaborative agreement with Bayer for that product, a seasoned and knowledgeable management team, a premier manufacturing process and facility, a healthy balance sheet and a strong intellectual property estate. And it sports one last thing: an attractive price. We note the possibility for outperforming our $13 price target if the Coagulin-B clinical data comes out strong." All their picks .... pbs.org John McCarthy